The pathogenesis of lipodystrophy caused by the HIV protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs) is unclear. We have investigated the disposition of these drugs in adipocytes and the consequent effect on adipocyte metabolism and viability.
Design
Laboratory study utilizing two murine cell lines, 3T3-L1 and 3T3-F442A.
Methods
Intracellular NRTI phosphate and PI concentrations were determined by HPLC and HPLC-MS/MS, respectively. The cytotoxicity of the drugs was examined on the different adipogenic stages together with their effects on glucose uptake plus or minus insulin, and on glycerol and triglyceride levels.
Results
There was rapid intracellular accumulation and phosphorylation of [3H]-zidovudine and -stavudine to their phosphate metabolites in adipocytes. The NRTIs were not cytotoxic, did not affect preadipocyte protein synthesis and did not inhibit adipogenesis or induce lipolysis. PIs accumulated in adipocytes (nelfinavir>saquinavir>ritonavir>indinavir). All PIs, except indinavir, were cytotoxic and inhibited adipogenesis, increased lipolysis and impaired preadipocyte protein synthesis. PIs inhibited glucose uptake in the rank order: indinavir>saquinavir>ritonavir>nelfinavir.
Conclusion
These data demonstrate that PIs may play a role in the insulin resistance observed in lipodystrophy by affecting glucose uptake, adipogenesis and lipolysis. NRTIs alone do not seem to have any effect on adipocyte metabolism despite undergoing phosphorylation to their triphosphorylated anabolites, although their effects in combination with PIs in perturbing adipocyte metabolism warrants further investigation.
CarrA., SamarasK., BurtonS., LawM., FreundJ., ChisholmD.J., & CooperD.A.A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS1998; 12: F51–F58.
4.
CarrA., SamarasK., ThorisdottirA., KaufmannG.R., ChisholmD.J., & CooperD.A.Diagnosis, prediction, and natural course of HIV-1 protease- inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet1999; 353: 2093–2099.
5.
HermieuJ.F., LeportC., RaveryV., DelmasV., & Boccon-GibodL.Lipodystrophy: a complication of protease inhibitors in HIV seropositive patients. Progres En Urologie1999; 9: 537–540.
6.
KotlerD.P.The epidemiology and pathogenesis of lipodystrophy in HIV disease: an update. The PRN Notebook2000; 5: 9–13.
7.
KuhelD.G., WoollettL.A., FichtenbaumC.J., & HuiD.Y.HIV protease inhibitor-induced hyperlipidemia and lipodystrophy is mediated through regulation of sterol responsive element binding protein (SREBP) responsive genes. Circulation2000; 102: 1767.
8.
DowellP., FlexnerC., KwiterovichP.O., & LaneM.D.Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. Journal of Biological Chemistry2000; 275: 41325–41332.
9.
RocheR., Poizot-MartinI., YazidiC.M., CompeE., GastautJ.A., TorresaniJ., & PlanellsR.Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS2002; 16: 13–20.
10.
CarrA., MillerJ., LawM., & CooperD.A.A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS2000; 14: F25–F32.
11.
Saint-MarcT., PartisaniM., Poizot-MartinI., RouviereO., BrunoF., AvellanedaR., LangJ.M., GastautJ.A., & TouraineJ.L.Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing anti-retroviral therapy: preliminary results of the LIPOCO study. AIDS2000; 14: 37–49.
MadgeS., Kinloch-de-LoesS., MerceyD., JohnsonM.A., & WellerI.V.D.Lipodystrophy in patients naive to HIV protease inhibitors. AIDS1999; 13: 735–737.
14.
van der ValkM., GisolfE.H., ReissP., WitF.W., JapourA., WeverlingG.J., & DannerS.A.; Prometheus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS2001; 15: 847–855.
15.
BognerJ.R., VielhauerV., BeckmannR.A., MichlG., WilleL., SalzbergerB., & GoebelF.D.Stavudine versus zidovudine and the development of lipodystrophy. Journal of Acquired Immune Deficiency Syndromes2001; 27: 237–244.
16.
WhiteA.J.Mitochondrial toxicity and HIV therapy. Sexually Transmitted Infections2001; 77: 158–173.
17.
BrinkmanK., SmeitinkJ.A., RomijnJ.A., & ReissP.Mitochondrial toxicity induced by nucleoside-analogue reverse- transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet1999; 354: 1112–1115.
18.
MoyleG.Mitochondrial toxicity hypothesis for lipoatrophy: a refutation. AIDS2001; 15: 413–415.
19.
WentworthJ.M., BurrisT.P., & ChatterjeeV.K.K.HIV protease inhibitors block human preadipocyte differentiation, but not via the PPAR gamma/RXR heterodimer. Journal of Endocrinology2000; 164: R7–R10.
20.
NguyenA.T., GagnonA., AngelJ.B., & SoriskyA.Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS2000; 14: 2467–2473.
21.
MoyleG.The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Drugs2001; 61: 19–26.
22.
GagnonA., AngelJ.B., & SoriskyA.Protease inhibitors and adipocyte differentiation in cell culture. Lancet1998; 352: 1032.
FrostS.C., & LaneM.D.Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes. Journal of Biological Chemistry1985; 260: 2646–2652.
25.
HoggardP.G., KewnS., BarryM.G., KhooS.H., & BackD.J.Effects of drugs on 2’,3′-dideoxy-2’,3′-didehydrothymidine phosphorylation in vitro.Antimicrobial Agents & Chemotherapy1997; 41: 1231–1236.
HansenM.B., NielsenS.E., & BergK.Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. Journal of Immunological Methods1989; 119: 203–210.
28.
JonesK., HoggardP.G., SalesS.D., KhooS., DaveyR., & BackD.J.Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS2001; 15: 675–681.
29.
VealG.J., & BackD.J.Metabolism of zidovudine. General Pharmacology1995; 26: 1469–1475.
30.
HoggardP., KhooS., BarryM., & BackD.Intracellular metabolism of zidovudine and stavudine in combination. Journal of Infectious Diseases1996; 174: 671–672.
31.
KewnS., HoggardP.G., SalesS.D., JonesK., MaherB., KhooS.H., & BackD.J.Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Antimicrobial Agents & Chemotherapy2002; 46: 135–143.
32.
SalesS.D., HoggardP.G., SunderlandD., KhooS., HartC.A., & BackD.J.Zidovudine phosphorylation and mitochondrial toxicity in vitro.Toxicology & Applied Pharmacology2001; 177: 54–58.
ZhangB., MacNaulK., SzalkowskiD., LiZ.H., BergerJ., & MollerD.E.Inhibition of adipocyte differentiation by HIV protease inhibitors. Journal of Clinical Endocrinology & Metabolism1999; 84: 4274–4277.
35.
RudichA., VanounouS., RiesenbergK., PoratM., TiroshA., Harman-BoehmI., GreenbergA.S., SchlaefferF., & BashanN.The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes2001; 50: 1425–1431.
36.
JainR.G., & LenhardJ.M.Select HIV protease inhibitors alter bone and fat metabolism ex vivo. Journal of Biological Chemistry2002; 277: 19247–19250.
37.
RanganathanS., & KernP.A.The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. Journal of Endocrinology2002; 172: 155–162.
38.
Blanchette-MackieE.J., DwyerN.K., BarberT., CoxeyR.A., TakedaT., RondinoneC.M., TheodorakisJ.L., GreenbergA.S., & LondosC.Perilipin is located on the surface layer of intracellular lipid droplets in adipocytes. Journal of Lipid Research1995; 36: 1211–1226.
39.
LondosC., Gruia-GrayJ., BrasaemleD.L., RondinoneC.M., TakedaT., DwyerN.K.Barber T, Kimmel AR & Blanchette-Mackie EJ. Perilipin: possible roles in structure and metabolism of intracellular neutral lipids in adipocytes and steroidogenic cells. International Journal of Obesity & Related Metabolic Disorders1996; 20(Suppl. 3): S97–S101.
40.
TanseyJ.T., SztalrydC., Gruia-GrayJ., RoushD.L., ZeeJ.V., GavrilovaO., ReitmanM.L., DengC.X., LiC., KimmelA.R., & LondosC.Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proceedings of the National Academy of Sciences, USA2001; 98: 6494–6499.
41.
MurataH., HruzP.W., & MuecklerM.The mechanism of insulin resistance caused by HIV protease inhibitor therapy. Journal of Biological Chemistry2000; 275: 20251–20254.
42.
NoorM.A., LoJ.C., MulliganK., SchwarzJ.M., HalvorsenR.A., SchambelanM., & GrunfeldC.Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS2001; 15: F11–F18.
AlexanderM., CurtisG., AvruchJ., & GoodmanH.M.Insulin regulation of protein biosynthesis in differentiated 3T3 adipocytes. Regulation of glyceraldehyde-3-phosphate dehydrogenase. Journal of Biological Chemistry1985; 260: 11978–11985.
45.
JohnM., NolanD., & MallalS.Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Therapy2001; 6: 9–20.
46.
MallalS.A., JohnM., MooreC.B., JamesI.R., & McKinnonE.J.Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS2000; 14: 1309–1316.
47.
MoyleG.Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?Drug Safety2000; 23: 467–481.
